Berkeley-based HexemBio is pioneering a groundbreaking therapy that replicates the embryonic conditions where blood stem cells first develop, offering an alternative to traditional chemical or genetic reprogramming of aged cells. Their flagship program focuses on improving outcomes for bone marrow transplants in blood cancer patients and has earned FDA Orphan Drug Designation. The company’s public debut comes with a $10.4 million seed funding led by prominent investors.
Back
